Streetbeat News

PHRRF

PharmaTher Holdings Ltd

Industry

Pharmaceutical Preparation Manufacturing

Open

0.15

Mkt cap

14M

Volume

65K

High

0.15

P/E Ratio

-3.82

52-wk high

0.32

Low

0.15

Div yield

N/A

52-wk low

0.10

PharmaTher Holdings Ltd. has filed a pre-submission facility correspondence for its novel racemic ketamine KETARX to the FDA, aiming for an expedited review. The company expects KETARX approval in Q1 2024 and a U.S. commercial launch in Q2 2024. Meanwhile, mental healthcare treatment provider Stella has acquired Field Trip’s U.S. assets to expand its treatment offerings. The acquisition will allow Stella to assume operations of Field Trip clinics in New York and Washington D.C.

Portfolio Pulse from Lara Goldstein

June 27, 2023 | 10:05 pm

PharmaTher Holdings has partnered with Vitruvias Therapeutics for the commercialization of its proprietary racemic ketamine products, KETARX, in the U.S. market. PharmaTher will be responsible for regulatory, manufacturing, and supply, while Vitruvias will handle marketing, sales, and distribution. PharmaTher plans to file its Abbreviated New Drug Application (ANDA) for KETARX with the FDA in early July and expects approval in Q1 2024.

Portfolio Pulse from Lara Goldstein

June 21, 2023 | 2:38 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.